California-based clinical stage biotech company Phanes Therapeutics, Inc. (Phanes) announced on Friday that it has received orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for its PT217, intended for the treatment of neuroendocrine carcinoma (NEC).
PT217, a first-in-class bispecific antibody, targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) and is being developed for patients with NEC. It received ODD for the treatment of small cell lung cancer (SCLC) from the FDA in 2022, and was granted Fast Track designation by the agency in 2024 for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression following platinum chemotherapy with or without a checkpoint inhibitor.
Earlier this year, Phanes signed a clinical supply agreement with Roche to study PT217 along with Roche's anti-PD-L1 therapy, atezolizumab.
Plus Therapeutics secures FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
AstraZeneca's Imfinzi recommended for EU approval in resectable NSCLC treatment
Qlucore launches first CE-marked diagnostic test for paediatric leukaemia
Summit Therapeutics and Pfizer partner to evaluate ivonescimab with ADCs in solid tumor trials
OS Therapies secures US patent for OST-HER2 manufacturing, extending exclusivity to 2040
Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL
Kexing Biopharm's GB05 IND application receives US FDA approval
AroCell secures Chinese patent for respiratory infection detection
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
Health Canada approves Merck's KEYTRUDA for resectable non-small cell lung cancer
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline